Urgent need to expand use of shingles vaccine and treat shingles-related pain

Shingles, a reactivation of the herpes zoster (chickenpox) virus affects nearly 1 in 3 Americans. About 1 million cases are diagnosed each year, with some patients suffering excruciating pain and itching due to post-herpetic neuralgia (PHN), a complication of the viral infection that can last for years despite treatment. The latest information on shingles and PHN, including a new, improved vaccine to prevent shingles and alternative therapies to control symptoms, are discussed in a special focus section in Population Health Management, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

The issue features an interview with Julie Gerberding, MD, MPH, president of the vaccines unit of Merck (MRK), the company that manufactures the vaccine, and former director of the Centers for Disease Control (CDC). It also includes a Roundtable discussion featuring a panel comprised of some of the world's leading experts on PHN including Rafael Harpaz, MD, from the Centers for Disease Control; an article on the biology underlying reactivation of the zoster virus; and a study focused on the role that nutrition may have in shingles therapy. Barbara Yawn, MD, MSc, Director of Research, Olmsted Medical Center and Adjunct Professor, Department of Family and Community Health, University of Minnesota, Rochester, MN, is the guest editor of the special section.

"Shingles can be a devastating condition, especially for who have a 30% chance of continuing to have the often debilitating pain of PHN," says Guest Editor Dr. Yawn. "This is a condition that deserves continuing attention from the public, physicians, and nurses, as well as researchers."

"This issue of is especially valuable because it captures the extensive research taking place on shingles and PHN, in addition to the treatment options that have been shown to reduce dramatically the number of shingles cases," says Editor-in-Chief David B. Nash, MD, MBA, Dean and Dr. Raymond C. and Doris N. Grandon Professor, Jefferson School of , Philadelphia, PA.

More information: The articles in this special section are available free on the Population Health Management website at www.liebertpub.com/pop.

Provided by Mary Ann Liebert, Inc./Genetic Engineering News

not rated yet
add to favorites email to friend print save as pdf

Related Stories

CDC finds most seniors don’t get shingles vaccination

Jan 11, 2011

Although a vaccine to prevent shingles has been available since 2006, less than 7 percent of U.S. seniors -- the demographic most frequently affected by the disease -- chose to receive the vaccination as of ...

New study alters long-held beliefs about shingles

Feb 01, 2011

For decades, medical wisdom about shingles has been that it's a once-in-a-lifetime experience. The commonly-held belief is that patients are protected from a recurrence of the herpes zoster virus, which causes shingles, after ...

Recommended for you

Paralysed with fear: The story of polio

47 minutes ago

Thanks to vaccination, polio has been pushed to the brink of extinction – but can we finish the job? This is one of the big questions which a Bristol academic addresses in his new book, published next week.

Meningococcal disease ID'd in men who have sex with men

19 hours ago

(HealthDay)—Following reports of invasive meningococcal disease (IMD) among men who have sex with men (MSM), the New York City (NYC) Department of Health and Mental Hygiene (DOHMH) has recommended that ...

User comments

More news stories

Antioxidant shows promise in Parkinson's disease

Diapocynin, a synthetic molecule derived from a naturally occurring compound (apocynin), has been found to protect neurobehavioral function in mice with Parkinson's Disease symptoms by preventing deficits in motor coordination.

No danger of cancer through gene therapy virus

In fall 2012, the European Medicines Agency (EMA) approved the modified adeno-associated virus AAV-LPL S447X as the first ever gene therapy for clinical use in the Western world. uniQure, a Dutch biotech company, had developed ...

Laughing gas does not increase heart attacks

(Medical Xpress)—Nitrous oxide—best known as laughing gas—is one of the world's oldest and most widely used anesthetics. Despite its popularity, however, experts have questioned its impact on the risk ...

Model recreates wear and tear of osteoarthritis

(Medical Xpress)—There's a reason osteoarthritis is often called wear-and-tear arthritis: Repeated stress on joints over time results in degeneration of the soft cartilage that normally distributes loads ...